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ABSTRACT
Background: Individuals with Parkinson’s disease
(PD) may have an increased risk of overall mortality
compared to the general population. Women may have
lower mortality rates from PD than men; however,
studies among women on the effect of PD on mortality
have been limited and may not have adequately
controlled for confounding by comorbidities.
Methods: We conducted a matched cohort study
among participants in the Women’s Health Study. 396
incident PD cases were identified through self-report.
Each PD case was matched by age to a comparator
who was alive and had the same modified Charlson
comorbidity score as the PD case. The PD cases and
matched comparators were followed for all-cause
mortality. Cox proportional hazards models adjusted
for age at the index date, smoking, alcohol
consumption, exercise and body mass index were used
to determine the association between PD and mortality.
Results: During a median of 6.2 years of follow-up,
72 women died (47 PD cases and 25 comparators).
The multivariable-adjusted HR for mortality was 2.60
(95% CI 1.56 to 4.32).
Conclusions: PD was associated with more than a
twofold increased risk of all-cause mortality among
women. Results are similar to those observed among
men.
INTRODUCTION
Parkinson’s disease (PD) is a progressive neu-
rodegenerative movement disorder charac-
terised by its cardinal features of tremor,
bradykinesia, rigidity and postural instability.
The incidence of PD increases with age with
an estimated overall incidence rate of 17 per
100 000 person-years.1 Men have higher inci-
dence rates compared to women, particularly
between the ages of 60 and 80 years.2 There
is increasing evidence that gender disparities
are not limited to PD incidence but are also
relevant in the context of PD symptoms,
treatment and disease prognosis.3
PD has been linked to an increased risk of
overall mortality compared to the general
population.4 5 Among men, PD is associated
with an approximately twofold increase in the
risk of all-cause mortality.5 It has been
hypothesised that women may have lower mor-
tality rates from PD than men.3 However, the
evidence comparing mortality rates according
to gender is inconclusive. The majority of
studies indicate that women may have lower
mortality rates compared to men,6–13 but some
studies suggest higher mortality rates among
women.14–17 Many prior studies, which esti-
mated mortality risks among females with PD,
have been small and between-study heterogen-
eity has impeded pooling effect estimates.4
Additionally, these studies may not have
adequately controlled for confounding by
comorbidities, and often included prevalent
cases of PD. Given the limited evidence and
limitations of previous studies, further studies
are warranted to evaluate the association
between PD and mortality risk among women
and help elucidate possible gender disparities
in relation to PD mortality.
We therefore performed an age-matched
and comorbidity-matched cohort study
among participants in the Women’s Health
Study (WHS) to determine whether PD may
increase the risk of mortality among women.
By using only incident cases of PD,
Strengths and limitations of this study
▪ We performed an age-matched and comorbidity-
matched cohort study to determine the associ-
ation between Parkinson’s disease (PD) and
mortality among women.
▪ Only incident cases of PD were used and deaths
were confirmed by medical record review.
▪ Our PD cases were based on self-reports of
physician diagnosis and we did not have infor-
mation on the Hoehn and Yahr stage or other
clinical information on severity of PD.
▪ Results on the association between PD and spe-
cific causes of death are limited due to the low
number of outcome events, and should be inter-
preted with caution.
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performing comorbidity-matching and having a large
underlying cohort, our study has several strengths com-
pared to previous research.
METHODS
The WHS was a randomised, placebo controlled trial of
the effects of low-dose aspirin and vitamin E in the
primary prevention of cardiovascular disease and cancer
among 39 876 women.18 19 After the end of the trial in
2004, women were asked if they would be willing to con-
tinue to be followed on an observational basis.
Observational follow-up is currently ongoing.
Women have received yearly questionnaires asking
about demographic, lifestyle and health information,
including physician-diagnosed PD. We identiﬁed 398
women who self-reported ‘yes’ to the question on
physician-diagnosed PD. Next, to balance the age and
comorbidity burden of PD cases and comparators, we
attempted to match each PD case to a comparator fol-
lowing previously developed methods.20 Brieﬂy, a partici-
pant was eligible to be a comparator if she was free from
PD at the time the case was diagnosed (the index date),
had the same age and same modiﬁed Charlson
comorbidity score as the case on the index date, and did
not report PD during the 5 years after the index date
(to avoid preclinical cases being included in the com-
parator group). However, we allowed the selection of
comparators who died within the ﬁrst 5 years after the
index date without reporting PD. The modiﬁed
Charlson comorbidity index, which reﬂects accumulated
comorbidity status (including myocardial infarction, con-
gestive heart failure, peripheral vascular disease, demen-
tia, chronic pulmonary disease, connective tissue
disease, ulcer disease, liver disease, diabetes, renal
disease, tumours, leukaemia, lymphoma, multiple
myeloma and AIDS) between study entry and index date
(ie, the date of reported physician-diagnosed PD), was
calculated using self-reported health information accord-
ing to previously developed methods.20 21 Of the 398
self-reported PD cases, we were able to match 396 PD
cases to comparators.
Our outcome of interest was all-cause mortality.
Mortality follow-up is over 99% complete in the WHS.
Deaths were identiﬁed by reports from family members
or next of kin, postal authorities and searches of the
National Death Index. Information on date and cause of
death was conﬁrmed through review of death certiﬁcates
and medical records by an end points committee of phy-
sicians. Only conﬁrmed causes of death were included
in our analysis.
PD cases and matched comparators were followed
from the date of diagnosis of the PD case to death, loss
to follow-up or the end of the study (31 December
2013), whichever occurred ﬁrst. Characteristics at base-
line (1993–1995) of the PD cases and comparators were
described using means for continuous variables and pro-
portions for categorical variables. Mean duration of PD
was calculated from PD onset to death, loss to follow-up
or end of study. We used Cox proportional hazards
models to calculate the HR between PD and death.
Since age is a strong risk factor for death, we used age
instead of time-on-study as our time scale for these ana-
lyses.22 Model one adjusted for age at the index date (in
years), Charlson comorbidities score at the index date
(continuous) and smoking status at baseline in WHS
(never, past and current). Although we matched on age
and Charlson comorbidity score at index date, when add-
itional covariates are included in the model, the match-
ing factors also need to be adjusted for to obtain
unbiased effect estimates.23 Model two additionally
adjusted for baseline alcohol consumption (rarely/never,
1–3 drinks/month, 1–6 drinks/week, ≥1 drink/day),
exercise (rarely/never, <1 time/week, 1–3 times/week,
≥4 times/week) and body mass index (<25 kg/m2, 25 to
<30 kg/m2, ≥30 kg/m2) as measured at enrolment into
WHS. Three women were missing information on
smoking status and were assigned to the reference
category (never smoker) and four women were missing
information on BMI and were assigned to the reference
category (<25 kg/m2).
We explored effect modiﬁcation by smoking status
(never vs ever smoking), disease duration (<5 years vs
≥5 years) and age on PD onset (<70 vs ≥70 years of age)
by stratiﬁcation. To test for statistically signiﬁcant effect
modiﬁcation, we included an interaction term in the
model and used a χ2 test to determine if the interaction
term was statistically signiﬁcant. All models adjusted for
age and models for disease duration and age at onset
were additionally adjusted for smoking status. We used a
competing risk Cox model adjusted for age and smoking
status to analyse the association between PD and three
competing causes of death: cardiovascular disease,
cancer or other illnesses. We considered a two-tailed
p<0.05 as statistically signiﬁcant.
RESULTS
The baseline characteristics of PD cases and age-
matched and comorbidity-matched controls are pre-
sented in table 1. As expected, baseline characteristics of
PD cases and comparators were similar, although PD
cases were less likely to report being a current or past
smoker at enrolment in the WHS.
During a median of 6.2 years of follow-up, 72 women
died (47 PD cases and 25 comparators). The
Kaplan-Meier curve for overall survival is displayed in
ﬁgure 1 and shows that the PD cases have increased risk
of death compared to the comparators (p value<0.01).
The age-adjusted and smoking-adjusted HR for mortality
was 2.65 (95% CI 1.60 to 4.37) and the multivariable-
adjusted HR was 2.60 (95% CI 1.56 to 4.32). An explora-
tory analysis observed that the HR was higher among
those who were never smokers (HR=4.01; 95% CI 1.81
to 8.86) than ever smokers (HR=1.75; 95% CI 0.88 to
3.45); however, the interaction between smoking and PD
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did not reach statistical signiﬁcance (p value=0.10). We
observed higher HRs among those with a longer disease
duration (≥5 years) (HR=3.43; 95% CI 1.58 to 7.44) than
shorter disease duration (<5 years) (HR=1.57; 95% CI 0.78
to 3.17); however, the interaction between disease duration
and PD was not statistically signiﬁcant (p value=0.12). The
association between PD and mortality was slightly higher
for those <70 years of age (HR=3.44; 95% CI 1.43 to 8.23)
than those ≥70 years of age (HR=2.21; 95% CI 1.19 to
4.11); however, the interaction between age at onset and
PD was not statistically signiﬁcant (p value=0.32).
In exploratory analyses, PD was associated with an
increased risk of death from cardiovascular disease
(HR=2.65; 95% CI 0.98 to 7.19), cancer (HR=1.59; 95%
CI 0.59 to 4.26), and other causes (HR=3.50; 95% CI
1.67 to 7.34).
DISCUSSION
In this age-matched and comorbidity-matched cohort
study among women, PD was associated with a more
than twofold increased risk of all-cause mortality. Results
are similar to those observed in a study among men
which also performed age matching and comorbidity
matching20 (HR=2.32; 95% CI 1.85 to 2.92). This sug-
gests that the effect of PD on risk of mortality is similar
in men and women.
Heterogeneity across studies enrolling women has pre-
vented the pooling of effect estimates from prior
studies.4 Effect estimates ranged from 1.01 to 3.64, with
12 of the 17 studies ﬁnding less than a twofold increase
in the risk of mortality among those with PD. The
current study was larger than many prior studies and
used comorbidity matching to control for confounding
by the presence of other diseases. Confounding by
comorbidities may result in an underestimate of the true
effect of PD on mortality. For example, some studies
have suggested that individuals with PD are less likely to
have a prior diagnosis of most cancers than individuals
without PD.24–26 Lack of adequate control for cancer
comorbidities would result in an underestimate of the
effect of PD on mortality. Similarly, smokers are less
likely to develop PD,27 but smoking is linked with several
other comorbidities. A higher prevalence of
smoking-related comorbidities among the matched
Figure 1 Kaplan Meier curves for the survival probability
among individuals with Parkinson’s disease (PD) and
matched comparators.
Table 1 Baseline characteristics of PD patients and age- and comorbidity- matched comparators
PD patients
n=396
Comparators
n=396
Mean age at randomization, years (SD) 58.7 (8.0) 58.7 (8.0)
Mean age at PD diagnosis, years (SD) 70.6 (8.8) n.a.
Mean duration of PD, years (SD) 6.7 (4.5) n.a.
History of smoking, n (%)
Never 241 (60.9) 191 (48.2)
Past 129 (32.6) 159 (40.2)
Current 26 (6.6) 46 (11.6)
Alcohol use, n (%)
Rarely/never 201 (50.8) 172 (43.4)
1-3 drinks/month 54 (13.6) 48 (12.1)
1-6 drinks/week 99 (25.0) 139 (35.1)
≥1 drink/day 42 (10.6) 37 (9.3)
Physical activity, n (%)
Rarely/never 180 (45.5) 149 (37.6)
<1/week 62 (15.7) 76 (19.2)
1-3 times/week 119 (28.5) 119 (30.1)
≥4 times/week 41 (10.4) 52 (13.1)
BMI (kg/m2), n (%)
<25 199 (50.6) 203 (51.4)
25-<30 131 (33.3) 120 (30.4)
≥30kg/m2 63 (16.0) 72 (18.2)
Mean Charlson comorbidity score, at index date (SD) 1.18 (1.44) 1.18 (1.44)
BMI, body mass index; NA, not applicable; PD, Parkinson’s disease.
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comparators without PD may also result in an underesti-
mate of the true effect of PD on mortality. Thus, the
higher effect estimate observed in this study may be par-
tially due to the improved methods of controlling for
confounding by comorbidities used in this study.
We observed some evidence that smoking status may
modify the effect of PD on mortality risk with the stron-
gest effect of PD on mortality being seen among never
smokers, which has also been observed in some,14 28 but
not all,20 29 prior studies.
Some limitations to our study should be noted.
Identifying PD, particularly in early disease stages, is
challenging in clinical and research settings and we
cannot rule out potential misclassiﬁcation.30 Our PD
cases were based on self-reports of physician diagnosis
and we did not have information on the Hoehn and
Yahr stage or other clinical information on severity of
PD. However, self-reported PD diagnoses have been
shown to be highly valid among male health profes-
sionals.20 31 Furthermore, participants who reported PD
within 5 years of the index date were excluded to reduce
the possibility of having participants with subclinical PD
in our comparator group. Our cohort was composed of
female health professionals who are primarily white,
which may limit the generalisability of our ﬁndings to
other racial or ethnic groups or to populations of differ-
ent socioeconomic status. Additionally, our results may
not be generalisable to populations with younger ages at
PD onset since the average age at PD onset in our popu-
lation was 70 years of age. Although we employed several
methods to control for confounding, residual confound-
ing may still be present. Our study design is a prospec-
tive comorbidity-matched study and some general
limitations inherent to the matching procedure may also
apply to our study. For example, by matching, we
restricted our study population to those individuals who
could be matched based on their age and comorbidity
proﬁle. This could potentially reduce the external validity
of our study. However, only 2 of our 398 PD cases could
not be matched in our study, so we do not expect a large
impact on the generalisability of our results. Our analyses
of potential effect modiﬁcation by smoking or age at
onset should be interpreted with caution given the low
power to detect effects in strata and the possibility of false-
positive ﬁndings when several subgroups are analysed.32
Finally, results on the association between PD and speciﬁc
causes of death are limited due to the low number of
outcome events, and should be interpreted with caution.
Our study has several strengths including the prospect-
ive design, large sample size, identiﬁcation of incident
PD cases and collection of a large amount of covariate
information that allowed us to perform comorbidity
matching as well as control for other lifestyle variables.
We carefully adjusted for age, a strong predictor of both
PD onset and mortality, by matching on age, using age
as the primary time scale in our analyses and including
it as a covariate in all analyses. Finally, all deaths were
conﬁrmed by review of medical records.
In conclusion, we observed that PD was associated
with an approximately twofold increase in the risk of
mortality among women in this population-based
comorbidity-matched cohort study.
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